Home » USA Broker Ratings » Sage Therapeutics, Inc. – Consenus Indicates Potential 45.2% Upside

Sage Therapeutics, Inc. – Consenus Indicates Potential 45.2% Upside

Sage Therapeutics, Inc. with ticker code (SAGE) now have 18 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 250 and 90 calculating the mean target price we have 202.5. Given that the stocks previous close was at 139.51 this now indicates there is a potential upside of 45.2%. The 50 day MA is 156.15 while the 200 day moving average is 167.13. The market capitalisation for the company is $7,093m. Visit the company website at: http://www.sagerx.com

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD). The company’s product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and sleep disorders; and SAGE-324, a novel neuroactive steroid that has completed Phase I clinical trials to treat various neurological conditions, including essential tremor and epileptiform disorders. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington’s disease, Alzheimer’s disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain; and SAGE-689, a novel GABAA receptor positive allosteric modulator that is in preclinical stage to treat acute and chronic CNS disorders. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217 in Japan, Taiwan, and South Korea. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.